Isofol has obtained a request to call for an extraordinary general meeting
Information in the press release below is intended for investors.
Isofol has obtained a request to call an extraordinary general meeting from shareholders representing a minority of at least 10 percent in order to take a decision on the election of a new board of directors. The notice to the extraordinary general meeting will be announced as soon as is practically possible.
For clarification, the board would like to point out that if the board’s proposal for liquidation is not approved at the extraordinary general meeting called by the board on February 13th, the entire board will make their seats available and will not be up for re-election at the extraordinary general meeting requested by the minority.
For further information, please contact
Isofol Medical AB (publ)
Jan Törnell, styrelseordförande
E-mail: jan.tornell@innoext.se
Jarl Ulf Jungnelius, M.D., CEO
E-mail: jungnelius@isofolmedical.com
Telephone: +46 709-16 89 55
The information was submitted for publication, through the agency of the contact person set out above, on January 30, 2023, at 13:45 CET.
About Isofol Medical AB (publ)
Isofol Medical AB (publ) is a clinical-stage biotechnology company that has focused its operations on developing and improving the current standard treatment for patients suffering from cancer by increasing treatment efficacy through the use of cytostatics. Isofol’s ambition was to develop a drug for first-line treatment of advanced colorectal cancer (mCRC), thereby seeking to improve the current clinical practice by realizing the full strength of 5-FU with the addition of arfolitixorin. Isofol has an exclusive global licensing agreement with Merck & Cie in Schaffhausen, Switzerland, to develop and commercialize arfolitixorin in oncology. Isofol Medical AB (publ) is traded on Nasdaq Stockholm.
